Given that patients with chronic inflammatory diseases showed the highest increase in CSF-associated CD133 (Figure 2), we performed a sub-analysis and grouped these 25 patients into relapsing-remitting multiple sclerosis (RRMS, including CIS; n = 7), secondary progressive multiple sclerosis (SPMS, n = 10), primary progressive multiple sclerosis (PPMS, n = 5) and patients with isolated myelitis (n = 3). The gene discussed is PROM1; the disease is in situ carcinoma.